Efficacy and Safety of Trastuzumab as a Single Agent in First-Line

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line trastuzumab The story of trastuzumab begins with Axel Ullrich's dedication to the concept that receptor tyrosine kinases must be the key to many human trastuzumab On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo,

trastuzumab For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication See our biosimilar pamphlet

trastuzumab Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease The story of trastuzumab begins with Axel Ullrich's dedication to the concept that receptor tyrosine kinases must be the key to many human